ストックスクリーナーアプリを入手
12.75
0.87%
0.11
アフターアワーズ：
12.73
-0.02
-0.16%
前日終値:
$12.64
開ける：
$12.62
24時間の取引高:
428.28K
Relative Volume:
1.58
時価総額：
$786.32M
収益：
-
当期純損益:
$-69.79M
株価収益率:
-10.46
EPS:
-1.2185
ネットキャッシュフロー:
$-54.55M
1週間 パフォーマンス:
+0.63%
1か月 パフォーマンス:
+25.99%
6か月 パフォーマンス:
+90.01%
1年 パフォーマンス:
+284.04%
1日の値動き範囲:
$12.44
$12.98
1週間の範囲:
$11.92
$12.98
52週間の値動き範囲:
$3.105
$12.98
Design Therapeutics Inc Stock (DSGN) Company Profile
名前
Design Therapeutics Inc
セクター
電話
858-293-4900
住所
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
12.75 | 779.54M | 0 | -69.79M | -54.55M | -1.2185 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 開始されました | Jefferies | Buy |
| 2026-01-07 | 開始されました | Oppenheimer | Outperform |
| 2025-12-03 | 開始されました | Craig Hallum | Buy |
| 2025-12-03 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-05-04 | アップグレード | Goldman | Sell → Neutral |
| 2022-06-10 | 開始されました | Wedbush | Outperform |
| 2022-05-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-19 | 開始されました | Goldman | Sell |
| 2021-04-20 | 開始されました | Goldman | Neutral |
| 2021-04-20 | 開始されました | Piper Sandler | Overweight |
| 2021-04-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Design Therapeutics Inc (DSGN) 最新ニュース
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings - MSN
Aug Movers: Can Design Therapeutics Inc expand its profit margins2026 Breakouts & Technical Entry and Exit Alerts - baoquankhu1.vn
We Think Design Therapeutics (NASDAQ:DSGN) Can Afford To Drive Business Growth - Yahoo Finance
FOMO Trade: Can Design Therapeutics Inc navigate macro headwinds2026 Price Action Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Astellas Licenses Dyno Therapeutics’ AI-Designed AAV Capsid, Advancing Gene Delivery for Muscle Disorders - BioPharm International
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings (XLV:NYSEARCA) - Seeking Alpha
US Market Wrap: What is the long term forecast for Design Therapeutics Inc stock2026 Volume Leaders & Proven Capital Preservation Methods - baoquankhu1.vn
DSGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design - Business Wire
PTCT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Design Therapeutics (NASDAQ:DSGN) Trading Up 6.8%Still a Buy? - MarketBeat
Panic Selling: What is the long term forecast for Design Therapeutics Inc stockMarket Risk Report & Community Verified Trade Alerts - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
DSGN.O PE Ratio & Valuation, Is DSGN.O Overvalued - Intellectia AI
DSGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oppenheimer initiates coverage of Design Therapeutics (DSGN) with outperform recommendation - MSN
Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month HighHere's What Happened - MarketBeat
Director David Shapiro granted 67,500 DSGN stock options (DSGN) - Stock Titan
Design Therapeutics (DSGN) director David Shapiro submits Form 3 - Stock Titan
Design Therapeutics, Inc. Appoints David Shapiro, M.D. as Class III Director and as Nominating and Corporate Governance Committee Member, Effective March 31, 2026 - marketscreener.com
David Shapiro joins Design Therapeutics (DSGN) board with equity awards - Stock Titan
DYN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Value Recap: Can Design Therapeutics Inc expand its profit marginsEarnings Miss & Capital Efficient Trading Techniques - baoquankhu1.vn
Asha Therapeutics Launches as First Atom Therapeutics, a Zero-Shot De Novo Drug Design Company - businesswire.com
DSGN.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Design Therapeutics (DSGN) price target increased by 12.82% to 14.96 - MSN
Fuchs Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen - barchart.com
Fed Meeting: Will Design Therapeutics Inc benefit from current market trendsDip Buying & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
DSGN Earnings History & Surprises | EPS & Revenue Results | DESIGN THERAPEUTICS INC (NASDAQ:DSGN) - ChartMill
Absci Reports Positive ABS-201 Clinical Progress, Strong Financials, and Advances AI-Designed Therapeutics Pipeline in 2025 Results - Minichart
DSGN Technical Analysis & Stock Price Forecast - Intellectia AI
Aug EndMonth: Will Design Therapeutics Inc benefit from green energy policies2026 Buyback Activity & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Dyno Therapeutics Launches Dyno Psi-Phi, an Agentic AI Suite for Protein Binder Design, at NVIDIA GTC 2026 - Business Wire
Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics - The Manila Times
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma - Barchart.com
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Design Therapeutics (DSGN) Receives a New Rating from a Top Analyst - The Globe and Mail
Design Therapeutics (NASDAQ:DSGN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Jefferies Initiates Coverage On Design Therap... - Benzinga
Design Therapeutics (NASDAQ:DSGN) Now Covered by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage on Design Therapeutics With Buy Rating, $15 Price Target - marketscreener.com
Jefferies initiates Design Therapeutics stock with buy on drug potential - Investing.com
Jefferies initiates Design Therapeutics stock with buy on drug potential By Investing.com - Investing.com Australia
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program - Yahoo Finance
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% on Analyst Upgrade - Defense World
Design Therapeutics Inc devrait afficher une perte de 33 cents par actionEarnings AVANT-PAPIER - TradingView
[SCHEDULE 13D/A] Design Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Aug Breakouts: Can Design Therapeutics Inc expand its profit margins2026 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% After Analyst Upgrade - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Design Therapeutics Inc (DSGN) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):